Cell therapy for type 2 diabetes: Is it desirable and can we get it?

Diabetes, Obesity and Metabolism

Volumn 10, Issue SUPPL. 4, 2008, Pages 205-211

  Halban, Philippe A ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

B cell regeneration; B cell replacement therapy; Cytokines; Islet inflammation; Type 2 diabetes

Indexed keywords

GLUCAGON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; ORAL ANTIDIABETIC AGENT;

CELL FUNCTION; CELL LINEAGE; CELL REGENERATION; CELL SURVIVAL; CELL THERAPY; CONFERENCE PAPER; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEFICIENCY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATHOPHYSIOLOGY; SUBSTITUTION THERAPY;

EID: 53549088025     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00957.x     Document Type: Conference Paper

References (44)

1. Modlin IM, Kidd M, Hults C, Hinoue T. Surgery of chronic pancreatitis: chronicle of confusion and despair. World J Surg 2002; 26: 1382-1396.
2. Ebstein W. Therapie des Diabetes Mellitus, insbesondere über die Anwendung des Salicylsauren Natron bei demselben. Berl Klin Wochenschr 1876; 24: 337-340.
3. Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
4. Kahn CR, Flier JS, Bar RS et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976; 294: 739-745.
5. Yalow RS, Berson SA. Plasma insulin concentrations in nondiabetic and early diabetic subjects: Determinations by a new sensitive immuno-assay technic. Diabetes 1960; 9: 254-260.
6. Maclean N, Ogilvie RF. Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes 1955; 4: 367-376.
7. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-368.
8. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970; 283: 109-115.
9. Unger RH, Orci L. The role of glucagon in the endogenous hyperglycemia of diabetes mellitus. Annu Rev Med 1977; 28: 119-130.
10. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
11. Weir GC, Bonner-Weir S. Islets of Langerhans: The puzzle of intraislet interactions and their relevance to diabetes. J Clin Invest 1990; 85: 983-987.
12. Weir GC, Leahy JL, Bonner-Weir S. Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes. Diabetes Metab Rev 1986; 2: 125-161.
13. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 2001; 50 (Suppl. 1): S160-S163.
14. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
15. Yoon KH, Ko SH, Cho JH et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88: 2300-2308.
16. Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 2004; 47: 581-589.
17. Clark A, Wells CA, Buley ID et al. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: Quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 1988; 9: 151-159.
18. Cerasi E, Luft R. Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs. Genetic control of insulin response? Acta Endocrinol (Copenh) 1967; 55: 330-345.
19. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
20. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: A new analysis. J Clin Endocrinol Metab 2005; 90: 493-500.
21. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
22. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: The 10-year follow-up of the Belfast Diet Study. Diabet Med 1998; 15: 290-296.
23. Mu J, Woods J, Zhou YP et al. Chronic inhibition of dipeptidyl peptidase-4 with a Sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-1704.
24. Robertson RP. Estimation of beta cell mass by metabolic tests: necessary, but how sufficient? Diabetes 2007; 56: 2420-2424.
25. Kroon E, Martinson LA, Kadoya K et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 2008; 26: 443-452.
26. Parnaud G, Bosco D, Berney T et al. Proliferation of sorted human and rat beta cells. Diabetologia 2008; 51: 91-100.
27. Halban PA. Cellular sources of new pancreatic beta cells and therapeutic implications for regnerative medicine. Nat Cell Biol 2004; 6: 1021-1025.
28. Halban PA, Kahn SE, Lernmark A, Rhodes CJ. Gene and cell-replacement therapy in the treatment of type 1 diabetes: How high must the standards be set? Diabetes 2001; 50: 2181-2191.
29. Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004; 429: 41-46.
30. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007; 117: 2553-2561.
31. Xu X, D'Hoker J, Stange G et al. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 2008; 132: 197-207.
32. Bonner-Weir S, Sharma A. Are there pancreatic progenitor cells from which new islets form after birth? Nat Clin Pract Endocrinol Metab 2006; 2: 240-241.
33. Dor Y. Beta-cell proliferation is the major source of new pancreatic beta cells. Nat Clin Pract Endocrinol Metab 2006; 2: 242-243.
34. Bonner-Weir S, Weir GC. New sources of pancreatic beta-cells. Nat Biotechnol 2005; 23: 857-861.
35. Butler PC, Meier JJ, Butler AE, Bhushan A. The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 2007; 3: 758-768.
36. Lindgren CM, McCarthy MI. Mechanisms of disease: Genetic insights into the etiology of type 2 diabetes and obesity. Nat Clin Pract Endocrinol Metab 2008; 4: 156-163.
37. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: A link between type 1 and type 2 diabetes. J Mol Med 2003; 81: 455-470.
38. Maedler K, Sergeev P, Ris F et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
39. Ehses JA, Perren A, Eppler E et al. Increased number of islet associated macrophages in type 2 diabetes. Diabetes 2007; 56: 2356-2370.
40. Maedler K, Sergeev P, Ehses JA et al. Leptin modulates β cell expression of IL-1 receptor antagonist and release of IL-1β in human islets. Proc Natl Acad Sci U S A 2004;101: 8138-8143.
41. Prentki M, Joly E, El-Assaad W, Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: Role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 2002; 51 (Suppl. 3): S405-S413.
42. Harding HP, Ron D. Endoplasmic reticulum stress and the development of diabetes: A review. Diabetes 2002; 51 (Suppl. 3): S455-S461.
43. Fonseca SG, Lipson KL, Urano F. Endoplasmic reticulum stress signaling in pancreatic beta-cells. Antioxid Redox Signal 2007; 9: 2335-2344.
44. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53 (Suppl. 1): S119-S124.